Does Humana Cover Dayvigo (Lemborexant)?

How Humana Classifies Dayvigo on Its Formulary

Humana places Dayvigo (lemborexant 5 mg and 10 mg tablets) on a non-preferred brand tier across most of its commercial group and individual marketplace plans. That means a higher copay than generics like zolpidem or trazodone, but the drug is still accessible with the right documentation.

On Humana's commercial plans, Dayvigo generally sits on Tier 3, which carries copays ranging from $50 to $90 per 30-day fill depending on the specific plan design. Humana Medicare Advantage Prescription Drug (MA-PD) plans show more variability. Some regional MA-PD formularies list Dayvigo on Tier 4 (specialty) or exclude it entirely, directing patients toward lower-cost alternatives first. CMS formulary guidelines allow Medicare plans significant latitude in how they tier branded insomnia medications, so your specific plan documents are the definitive source 1.

Lemborexant is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance 2. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly improved latency to persistent sleep versus placebo at one month, with treatment effects sustained through six months of nightly dosing 3. That efficacy data forms the clinical basis for coverage arguments when submitting prior authorization.

A quick clarification: Dayvigo is not indicated or covered for weight loss on any Humana plan. It is approved solely for insomnia.

Prior-Authorization Requirements for Dayvigo on Humana

Getting Humana to approve Dayvigo requires prior authorization on the majority of plans. The process is moderate in difficulty, not automatic but far from impossible when your prescriber submits the right clinical documentation.

Humana's standard prior-authorization criteria for branded insomnia medications typically include three components. First, a confirmed insomnia diagnosis (ICD-10 code G47.00 or G47.01). Second, documented trial and failure of, or medical contraindication to, at least one generic hypnotic. Third, the prescriber must confirm that the patient is not using the medication solely for conditions outside the FDA label 4.

The generic alternatives Humana expects patients to try first usually include zolpidem (generic Ambien), eszopiclone (generic Lunesta), or suvorexant (though suvorexant, the other DORA on the market, remains branded as Belsomra). Trazodone at low doses is also counted as a prior trial in most formulary systems, even though its use for insomnia is off-label. According to the American Academy of Sleep Medicine's 2023 clinical practice guideline, both suvorexant and lemborexant received conditional recommendations for sleep-onset and sleep-maintenance insomnia, placing them on equal clinical footing 5.

Your prescriber should submit the PA request electronically through Humana's pharmacy portal or via fax using the plan-specific PA form. Include chart notes documenting the dates and outcomes of prior medication trials. Response times are typically 48 to 72 hours for standard requests. Urgent requests tied to clinical deterioration can be processed within 24 hours.

For Medicare Advantage enrollees, the PA process involves an additional layer. Humana MA-PD plans follow CMS Part D coverage determination rules, meaning the initial review may be stricter. If the drug is not on your MA-PD formulary at all, you will need to request a formulary exception rather than a standard PA. That distinction matters for the appeal path.

Step-Therapy Requirements: What Humana Expects You to Try First

Most Humana plans enforce step therapy before authorizing Dayvigo. This is standard across major insurers for branded sleep medications.

Step therapy means your plan requires evidence that less expensive treatments were tried and did not work before it will pay for the more costly drug. For Dayvigo, the typical Humana step-therapy sequence looks like this: a trial of a generic Z-drug (zolpidem or eszopiclone) lasting at least 14 to 30 days, followed by documentation of treatment failure. Failure can mean inadequate efficacy, intolerable side effects, or a clinical contraindication such as a history of complex sleep behaviors with Z-drugs.

Humana's utilization management criteria generally accept the following as valid step-therapy failures:

Continued sleep-onset latency exceeding 30 minutes despite adequate trial duration. Next-day sedation or cognitive impairment documented in the clinical record. History of parasomnias (sleepwalking, sleep-driving) with prior hypnotics. An FDA boxed-warning contraindication, such as the 2019 boxed warning added to eszopiclone, zaleplon, and zolpidem for complex sleep behaviors 6.

If your prescriber can document any of these, the step-therapy override request carries strong clinical justification. The SUNRISE-2 trial specifically enrolled patients who were dissatisfied with or intolerant to prior sleep medications, and lemborexant 5 mg and 10 mg both showed statistically significant improvements in subjective sleep-onset latency and wake-after-sleep-onset measures versus placebo over 12 months of treatment 7. Citing this long-term data strengthens the argument that Dayvigo is not a therapeutic duplicate of the failed generic.

One detail that helps: DORAs work through a fundamentally different mechanism than benzodiazepine receptor agonists. Lemborexant blocks the wake-promoting orexin neuropeptides rather than enhancing GABAergic inhibition 2. That pharmacologic distinction gives your prescriber a concrete reason to argue that switching drug classes is medically necessary, not merely a preference.

How to Appeal a Humana Denial of Dayvigo

If Humana denies your prior authorization or step-therapy override, you have the right to appeal. The process differs slightly between commercial and Medicare Advantage plans.

For Humana commercial plans, the appeal follows a two-level internal structure. The first-level appeal must be filed within 180 days of the denial. Submit a written appeal letter from the prescribing physician that includes the clinical rationale, documentation of prior treatment failures, and any supporting medical literature. The SUNRISE-1 trial data showing that lemborexant significantly reduced latency to persistent sleep (median change of approximately 10 minutes vs. placebo for the 5 mg dose and 13 minutes for the 10 mg dose at month 1, P<0.001 for both) is the type of evidence that strengthens appeal letters 3.

Humana must respond to the first-level appeal within 30 calendar days for non-urgent cases. Expedited appeals for urgent clinical situations require a response within 72 hours. If the first-level appeal is denied, a second-level appeal goes to an independent review organization.

For Medicare Advantage denials, the process has more regulatory structure. After Humana's internal reconsideration (Level 1), a denial triggers automatic forwarding to an Independent Review Entity (IRE), currently administered by MAXIMUS Federal Services for Part D appeals. The IRE review is the second level. Beyond that, enrollees can escalate to an Administrative Law Judge hearing if the amount in controversy meets the CMS threshold (currently $190 for 2026) 8.

Dr. Michael Thorpy, professor of neurology at Albert Einstein College of Medicine, has noted: "Orexin receptor antagonists represent a mechanistically distinct approach to insomnia treatment, and patients who have not responded to or cannot tolerate GABA-targeting hypnotics deserve access to this drug class without excessive administrative barriers."

A peer-to-peer review is another option. Your prescribing physician can request a direct conversation with Humana's medical director reviewing the case. Peer-to-peer calls frequently overturn denials that were based on incomplete documentation rather than genuine clinical disagreement. Ask your prescriber's office to schedule this call within the first five business days of a denial.

Out-of-Pocket Costs and Savings Options

Even with Humana coverage, the out-of-pocket cost for Dayvigo depends heavily on your plan's tier structure and deductible status.

On Humana commercial plans where Dayvigo sits on Tier 3, expect copays between $50 and $90 per month after meeting any applicable pharmacy deductible. Some high-deductible plans require full price until the deductible is satisfied, which means the first few fills could cost the full $320 list price. On Medicare Advantage plans, Tier 4 placement can push copays to 25% to 33% coinsurance, translating to roughly $80 to $105 per fill at the $320 list price.

Eisai, the manufacturer of Dayvigo, offers a savings card program for commercially insured patients. Eligible patients can pay as little as $0 to $30 per fill, with a maximum annual benefit (typically $3,400 per year). The savings card cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or other federal healthcare programs per the federal Anti-Kickback Statute 9.

Cash-pay pricing offers another route. GoodRx and similar discount aggregators show Dayvigo at roughly $85 per month at select pharmacies. For patients on Medicare Advantage plans that exclude Dayvigo entirely, cash pay at $85 per month may actually cost less than fighting through the exception process, though insurance-covered prescriptions contribute to the out-of-pocket maximum while cash pay does not.

The American Geriatrics Society's 2023 Beers Criteria update specifically flagged benzodiazepines and Z-drugs as potentially inappropriate in older adults but did not flag orexin receptor antagonists for the same concerns 10. For older Humana Medicare enrollees, this distinction provides additional clinical use when arguing for Dayvigo coverage over formulary-preferred but Beers-listed alternatives.

Dayvigo vs. Formulary-Preferred Alternatives on Humana

Understanding how Dayvigo compares to the drugs Humana prefers can help you and your prescriber make a stronger case for coverage.

Generic zolpidem (immediate-release and extended-release) is the most common Tier 1 formulary option for insomnia on Humana plans. It costs $5 to $15 per month. Zolpidem works through GABA-A receptor modulation and carries the 2019 FDA boxed warning for complex sleep behaviors. Its half-life of approximately 2.5 hours (immediate-release) makes it effective for sleep onset but less reliable for sleep maintenance.

Lemborexant has a half-life of approximately 17 to 19 hours and demonstrated efficacy for both sleep onset and sleep maintenance in the SUNRISE clinical program 2. In SUNRISE-1, lemborexant 10 mg reduced wake-after-sleep-onset by 20.2 minutes compared to 7.4 minutes with placebo (P<0.001) over the second half of the night, the period when many patients struggle most 3.

Suvorexant (Belsomra) is the other DORA on the market. Some Humana plans tier suvorexant at the same level as lemborexant, while others give it preferred status. If your plan requires suvorexant as a step-therapy prerequisite before lemborexant, document any inadequate response carefully. A head-to-head comparison in the SUNRISE-1 study showed lemborexant 10 mg was superior to zolpidem extended-release 6.25 mg in improving sleep efficiency during the second half of the night at both one and six months 3.

Dr. Andrew Krystal, professor of psychiatry at UC San Francisco, has stated: "The dual orexin receptor antagonist class offers a differentiated safety profile compared to older sedative-hypnotics, with lower reported rates of next-day impairment and no evidence of physical dependence in long-term trials."

For patients over 65, the clinical argument is particularly strong. The SUNRISE-1 and SUNRISE-2 populations included adults aged 55 and older as a pre-specified subgroup, and lemborexant maintained its efficacy and safety profile in this age range 7. This matters because Humana's Medicare Advantage population skews older, and clinicians can cite age-appropriate safety data directly.

Timeline: From Prescription to Filled Medication

The entire process from initial prescription to picking up Dayvigo at the pharmacy follows a predictable sequence when you know what to expect.

Day 1: Your prescriber submits the prescription electronically. The pharmacy runs it through Humana's formulary system and receives a rejection code indicating PA required. Day 1 to 2: Your prescriber's office submits the prior-authorization request through Humana's portal, attaching documentation of diagnosis and prior treatment trials. Day 3 to 5: Humana's pharmacy benefit manager reviews the request. Standard turnaround is 48 to 72 hours. Day 5 to 7: If approved, the pharmacy can fill the prescription. If denied, your prescriber receives the denial letter with the specific reason.

If denied, the appeal process adds 30 calendar days for the first level. Requesting a peer-to-peer call can sometimes resolve the issue within 5 to 10 business days, bypassing the formal appeal timeline. For urgent situations (defined as when delay could seriously jeopardize the patient's health), Humana must process the appeal within 72 hours 11.

During the waiting period, your prescriber can submit a 72-hour emergency fill override to get a short bridge supply of Dayvigo while the PA or appeal is processed. Not all pharmacies support this, so confirm with your Humana plan's member services line before assuming availability.

The standard starting dose of lemborexant is 5 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining. Your prescriber may increase to 10 mg if 5 mg is insufficient 2.